Researchers identified how the circadian gene PER2 regulates intracellular cholesterol synthesis in oral squamous cell carcinoma, pointing to a potential chronotherapy angle with simvastatin. The study positions cholesterol metabolism as a modifiable dependency controlled by PER2, with reported work suggesting simvastatin efficacy may be enhanced by aligning with the PER2-linked pathway.